Winton Group’s Lexeo Therapeutics LXEO Stock Holding History

Winton Group’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-26,900	Closed	-$267K	–	1275
2025 Q4	$267K	Buy	+26,900	New	+$245K	0.01%	769

Other funds holding LXEO

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Winton Group's LXEO Position: Q1 2026 in Review

Winton Group sold out of Lexeo Therapeutics (LXEO) in Q1 2026, closing a stake of 26,900 shares — an estimated $267K sold.

Winton Group first reported a position in LXEO in Q4 2025 and held it in 1 quarter. The position peaked at $267K in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

Winton Group reported no remaining Lexeo Therapeutics position as of Q1 2026 after selling out during the quarter.
Winton Group sold 26,900 Lexeo Therapeutics shares in Q1 2026, an estimated $267K.
Winton Group first reported a position in Lexeo Therapeutics in Q4 2025 and held it in 1 quarter.
Winton Group's Lexeo Therapeutics position peaked at $267K in Q4 2025.
139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Winton Group's 13F filing for Q1 2026, filed 12 May 2026.